Patients 80 and older who are treated with single-agent immunotherapies for some cancers benefit from these innovative treatments and have somewhat comparable outcomes to younger people who received the same type of treatments for similar cancers, according to a landmark study published November 4, in the journal JAMA Oncology

OU College of Medicine researcher Jody Summers, Ph.D., recently discovered one of the body’s regulators of inflammation, a protein called Interleukin-6 (IL-6), plays a role in the development of myopia.

Desiree Azizoddin, PsyD, a behavioral scientist and pain psychologist joins TSET Health Promotion Research Center (HPRC) at the University of Oklahoma Health Sciences Center.

Thanh C. Bui's $3.6 million grant focuses on behavioral interventions for cancer control and prevention in high-risk populations.